Sirona Biochem Corp. (TSX-V: SBM) has successfully executed a strategic investment agreement with German-based investor Promura GmbH, securing $3 million CAD in unsecured, 12% convertible debentures. The biotechnology company, which specializes in cosmetic ingredients and drug discovery, has also signed a Letter of Intent (LOI) with Promura to establish a new joint venture focused on dermatological and cosmetic innovation.
The new subsidiary, Sirona Laboratories, will be established in Luxembourg and will handle the exclusive distribution of anti-aging products based on Sirona's TFC-1326 active ingredient. This partnership represents a significant milestone in Sirona's growth strategy and commercialization efforts for its proprietary anti-aging product line.
Strategic Investment Details
Promura GmbH has expressed its intention to invest up to an additional $12 million CAD into Sirona Laboratories, contingent upon the completion of due diligence procedures and fulfillment of specific conditions. Beyond the financial investment, Promura will provide experienced personnel to manage operations, leveraging their extensive industry expertise in cosmetics and dermaceuticals.
Dr. Howard Verrico, CEO of Sirona Biochem, expressed enthusiasm about the partnership: "We are thrilled to partner with Promura GmbH and are excited about the strong foundation this investment provides for Sirona's future and the establishment of a subsidiary, Sirona Laboratories. The additional investment, pending due diligence, will further strengthen our position in the market and help us accelerate the commercialization of our anti-aging product line."
Allocation of Funds
The proceeds from the initial private placement will be directed toward several key areas:
- General working capital
- Ongoing research and development
- Commercialization of Sirona's proprietary anti-aging product line
- Completion of overdue audited financial statements and annual Management's Discussion and Analysis
The last point addresses a cease trade order issued by the British Columbia Securities Commission on March 6, 2025, highlighting the company's commitment to resolving regulatory compliance issues.
Timeline and Additional Financing
The financing is expected to close within 60 days. In the interim, Sirona plans to announce a smaller bridge financing to support its immediate objectives. The completion of the private placement remains subject to customary conditions, including acceptance from the Toronto Stock Exchange Venture (TSXV).
Sirona's Technological Platform
Sirona Biochem specializes in stabilizing carbohydrate molecules to improve efficacy and safety in both cosmetic and pharmaceutical applications. The company's proprietary platform technology has yielded compounds that are licensed to leading companies worldwide, generating revenue through licensing fees, milestone payments, and ongoing royalties.
The company's laboratory, TFChem, located in France, has received multiple French national scientific awards and grants from both the European Union and French government, underscoring the scientific credibility of Sirona's research efforts.
Market Implications
The anti-aging market represents a significant growth opportunity within the health and wellness industry. With this strategic partnership, Sirona aims to accelerate its entry into this lucrative segment, leveraging its innovative TFC-1326 active ingredient.
The formation of Sirona Laboratories as a dedicated entity for dermatological and cosmetic innovation signals the company's commitment to establishing a stronger market presence in the cosmeceutical sector, potentially opening new revenue streams and enhancing shareholder value.
About Promura GmbH
Promura GmbH is a Germany-based investor group that focuses on supporting innovative biotechnology companies in their development and expansion phases. With expertise spanning insurance, loans, investment, and real estate sectors, Promura aims to contribute to the growth of companies developing breakthrough technologies.
This partnership with Sirona Biochem represents Promura's strategic interest in the biotechnology sector, particularly in companies with promising proprietary technologies and commercial potential.
